IL1B and type 2 diabetes mellitus: Dealing with such complexity could, however, be facilitated by the use of mathematical modeling and, in this case, by attaining a quantitative understanding of the disease processes underlying T2DM pathophysiology and the documented effect of IL-1β therapies on these pathways ex vivo.